Researchers at Health Diagnostic Laboratory Inc. (HDL Inc.) have developed a novel, proprietary method to measure atherogenic lipoprotein(a) particle concentration [Lp(a)-P]. The new method relies on modern immuno-electrophoretic techniques that separate and identify particles based on their charge and size, as opposed to current assays that measure either the amount of cholesterol contained in the Lp(a) fraction or, more commonly, the total mass of the Lp(a) particles in the circulation.
"With this breakthrough in Lp(a) analytical methodology, we are finally able to assess Lp(a) particle concentrations - which we think can be more powerful than Lp(a) mass or cholesterol - as predictors of cardiovascular risk," said Joseph McConnell, PhD, senior author of the paper and president and CEO of HDL Inc.
Read more:
Health Diagnostic Laboratory Announces First Lipoprotein(a) Particle Concentration Assay
Source: ADVANCE
No comments:
Post a Comment